Clinical Trial Update: A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) [Phase 3]

View source ↗

Summary

Phase 3 trial update for vericiguat (MK-1242) in heart failure with reduced ejection fraction; results for study MK-1242-035 have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Vericiguat (vericiguat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Heart Failure With Reduced Ejection Fraction | Phase 3 | Status: COMPLETED | Results posted: 2025-12-19